Soleno Therapeutics (SLNO) Total Non-Current Liabilities (2013 - 2026)

Soleno Therapeutics (SLNO) has reported Total Non-Current Liabilities for 14 consecutive years, with $111.2 million the latest figure, recorded in Q1 2026.

• In Q1 2026, Total Non-Current Liabilities rose 29.73% year-over-year to $111.2 million; the TTM figure through Mar 2026 stood at $111.2 million (up 29.73% YoY), while the FY2025 annual figure was $113.2 million, up 59.27% from the prior year.
• Total Non-Current Liabilities slipped to $111.2 million in Q1 2026 per SLNO's latest filing, from $113.2 million in the prior quarter.
• Across five years, Total Non-Current Liabilities topped out at $113.2 million in Q4 2025 and bottomed at $7.2 million in Q2 2022.
• Historically, Total Non-Current Liabilities has averaged $41.5 million across 5 years, with a median of $13.5 million in 2024.
• Annual changes were most pronounced in 2024 — Total Non-Current Liabilities plunged 41.25% — and 2025, when it soared 838.95%.
• Soleno Therapeutics' Total Non-Current Liabilities stood at $7.3 million in 2022, then surged by 59.08% to $11.6 million in 2023, then soared by 510.81% to $71.1 million in 2024, then jumped by 59.27% to $113.2 million in 2025, then dropped by 1.79% to $111.2 million in 2026.
• Business Quant data shows SLNO's Total Non-Current Liabilities at $111.2 million in Q1 2026, $113.2 million in Q4 2025, and $104.7 million in Q3 2025.